Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
25.92
+0.10 (0.39%)
Mar 6, 2026, 10:33 AM EST - Market open
Capricor Therapeutics Employees
Capricor Therapeutics had 160 employees as of December 31, 2024. The number of employees increased by 58 or 56.86% compared to the previous year.
Employees
160
Change (1Y)
58
Growth (1Y)
56.86%
Revenue / Employee
$69,566
Profits / Employee
-$512,435
Market Cap
1.34B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Immatics | 645 |
| Day One Biopharmaceuticals | 178 |
| Zenas BioPharma | 130 |
| MoonLake Immunotherapeutics | 130 |
| DBV Technologies | 117 |
| ORIC Pharmaceuticals | 106 |
| Savara | 59 |
| AtaiBeckley | 54 |
CAPR News
- 2 months ago - Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy Transcript - Seeking Alpha
- 3 months ago - Capricor: Maintaining 'Hold' Rating On Randomized Phase 3 HOPE-3 Trial Win With Deramiocel - Seeking Alpha
- 3 months ago - Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy Transcript - Seeking Alpha
- 3 months ago - Capricor Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 3 months ago - Capricor Stock Soars, Shkreli Is Short: Here's What Pharma Bro Had To Say - Benzinga
- 3 months ago - Capricor Therapeutics Duchenne Treatment Shows Strong Heart And Muscle Results In Trial - Benzinga
- 3 months ago - Capricor's muscle disorder cell therapy succeeds in late-stage study - Reuters
- 3 months ago - Martin Shkreli Takes Aim At Capricor — Stock Sinks - Benzinga